<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font18 { font-size : 18; } .font19 { font-size : 19; } .font24 { font-size : 24; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">headache </span>
   <span class="font24">treatment </span>
   <span class="font19">migraine </span>
   <span class="font18">effect </span>
   <span class="font15">pain </span>
   <span class="font14">medication </span>
   <span class="font14">tension-type </span>
   <span class="font14">patients </span>
   <span class="font14">overuse </span>
   <span class="font13">attacks </span>
   <span class="font13">Table </span>
   <span class="font13">cluster </span>
   <span class="font13">aura </span>
   <span class="font13">dose </span>
   <span class="font13">Headache </span>
   <span class="font12">analgesics </span>
   <span class="font12">patient </span>
   <span class="font12">symptoms </span>
   <span class="font12">children </span>
   <span class="font12">increased </span>
   <span class="font12">effects </span>
   <span class="font12">prophylactic </span>
   <span class="font12">typical </span>
   <span class="font12">chronic </span>
   <span class="font12">risk </span>
   <span class="font12">trigeminal </span>
   <span class="font12">Prophylactic </span>
   <span class="font12">headache. </span>
   <span class="font12">daily </span>
   <span class="font12">severe </span>
   <span class="font12">used </span>
   <span class="font12">attack </span>
   <span class="font12">day </span>
   <span class="font11">Migraine </span>
   <span class="font11">and/or </span>
   <span class="font11">following </span>
   <span class="font11">headache, </span>
   <span class="font11">criteria </span>
   <span class="font11">(see </span>
   <span class="font11">./j.-...x </span>
   <span class="font11">headaches </span>
   <span class="font11">neuralgia </span>
   <span class="font11">case </span>
   <span class="font11">cases </span>
   <span class="font11">study </span>
   <span class="font11">types </span>
   <span class="font11">Neurology </span>
   <span class="font11">Treatment </span>
   <span class="font11">acute </span>
   <span class="font11">e.g. </span>
   <span class="font11">generally </span>
   <span class="font11">given </span>
   <span class="font11">physical </span>
   <span class="font11">primary </span>
   <span class="font11">women </span>
   <span class="font11">{border-style </span>
   <span class="font11">diagnosis </span>
   <span class="font11">examination </span>
   <span class="font11">secondary </span>
   <span class="font11">cerebral </span>
   <span class="font11">days </span>
   <span class="font11">evidence </span>
   <span class="font11">general </span>
   <span class="font11">px;} </span>
   <span class="font11">typically </span>
   <span class="font11">#ffffff;} </span>
   <span class="font11">condition </span>
   <span class="font11">frequently </span>
   <span class="font11">lasting </span>
   <span class="font11">months </span>
   <span class="font11">neurological </span>
   <span class="font11">years </span>
   <span class="font11">assessment </span>
   <span class="font11">caused </span>
   <span class="font11">conditions </span>
   <span class="font11">episodic </span>
   <span class="font11">menstrual </span>
   <span class="font11">studies </span>
   <span class="font11">weeks </span>
   <span class="font11">Danish </span>
   <span class="font11">Neurol </span>
   <span class="font11">[G./N] </span>
   <span class="font11">facial </span>
   <span class="font11">guidelines </span>
   <span class="font11">including </span>
   <span class="font11">majority </span>
   <span class="font11">medical </span>
   <span class="font11">occur </span>
   <span class="font11">occurs </span>
   <span class="font11">period </span>
   <span class="font11">trigger </span>
   <span class="font11">triptans </span>
   <span class="font11">Cephalalgia </span>
   <span class="font11">Sect. </span>
   <span class="font11">contraceptive </span>
   <span class="font11">diagnostic </span>
   <span class="font11">effective </span>
   <span class="font11">frequent </span>
   <span class="font11">fulfilling </span>
   <span class="font11">headache: </span>
   <span class="font11">medications </span>
   <span class="font11">times </span>
   <span class="font11">use </span>
   <span class="font11">Jensen </span>
   <span class="font11">MOH </span>
   <span class="font11">Pharmacological </span>
   <span class="font11">combination </span>
   <span class="font11">information </span>
   <span class="font11">min </span>
   <span class="font11">nerve </span>
   <span class="font11">seen </span>
   <span class="font11">sumatriptan </span>
   <span class="font11">unilateral </span>
   <span class="font10">Diagnosis </span>
   <span class="font10">Non-pharmacological </span>
   <span class="font10">associated </span>
   <span class="font10">cases, </span>
   <span class="font10">dosage </span>
   <span class="font10">doses </span>
   <span class="font10">factors </span>
   <span class="font10">nausea, </span>
   <span class="font10">non-pharmacological </span>
   <span class="font10">performed </span>
   <span class="font10">primarily </span>
   <span class="font10">stress </span>
   <span class="font10">Cluster </span>
   <span class="font10">days/month </span>
   <span class="font10">discontinuation </span>
   <span class="font10">duration </span>
   <span class="font10">followed </span>
   <span class="font10">history </span>
   <span class="font10">important </span>
   <span class="font10">include </span>
   <span class="font10">migraine. </span>
   <span class="font10">mild </span>
   <span class="font10">minimum </span>
   <span class="font10">need </span>
   <span class="font10">pills </span>
   <span class="font10">programme </span>
   <span class="font10">support </span>
   <span class="font10">vomiting </span>
   <span class="font10">Sumatriptan </span>
   <span class="font10">activity </span>
   <span class="font10">age </span>
   <span class="font10">attempted </span>
   <span class="font10">correct </span>
   <span class="font10">effects. </span>
   <span class="font10">essential </span>
   <span class="font10">extent </span>
   <span class="font10">increase </span>
   <span class="font10">initial </span>
   <span class="font10">intake </span>
   <span class="font10">medicine </span>
   <span class="font10">occurring </span>
   <span class="font10">onset </span>
   <span class="font10">particularly </span>
   <span class="font10">pharmacological </span>
   <span class="font10">prophylaxis </span>
   <span class="font10">recommended </span>
   <span class="font10">related </span>
   <span class="font10">scientific </span>
   <span class="font10">tablets </span>
   <span class="font10">&amp;gt; </span>
   <span class="font10">Acute </span>
   <span class="font10">Attacks </span>
   <span class="font10">Bâ€“D </span>
   <span class="font10">Clinical </span>
   <span class="font10">Denmark. </span>
   <span class="font10">Effect </span>
   <span class="font10">Eur </span>
   <span class="font10">Olesen </span>
   <span class="font10">Pain </span>
   <span class="font10">Physical </span>
   <span class="font10">Use </span>
   <span class="font10">adults </span>
   <span class="font10">basis </span>
   <span class="font10">demonstrated </span>
   <span class="font10">disorder </span>
   <span class="font10">disorders </span>
   <span class="font10">documented </span>
   <span class="font10">effect. </span>
   <span class="font10">experience </span>
   <span class="font10">first-line </span>
   <span class="font10">following: </span>
   <span class="font10">individual </span>
   <span class="font10">intensity </span>
   <span class="font10">limited </span>
   <span class="font10">management </span>
   <span class="font10">nausea </span>
   <span class="font10">necessary </span>
   <span class="font10">needed </span>
   <span class="font10">number </span>
   <span class="font10">pressure </span>
   <span class="font10">quality </span>
   <span class="font10">second </span>
   <span class="font10">simple </span>
   <span class="font10">taken </span>
   <span class="font10">treated </span>
   <span class="font10">treatment. </span>
   <span class="font10">treatments </span>
   <span class="font10">week </span>
   <span class="font10">(Table </span>
   <span class="font10">Attack </span>
   <span class="font10">Background </span>
   <span class="font10">Generally, </span>
   <span class="font10">Patients </span>
   <span class="font10">[], </span>
   <span class="font10">accompanied </span>
   <span class="font10">achieved </span>
   <span class="font10">approximately </span>
   <span class="font10">attributed </span>
   <span class="font10">based </span>
   <span class="font10">characteristics </span>
   <span class="font10">considerable </span>
   <span class="font10">considerably </span>
   <span class="font10">daily. </span>
   <span class="font10">diagnosis, </span>
   <span class="font10">diary </span>
   <span class="font10">doses. </span>
   <span class="font10">exclude </span>
   <span class="font10">guideline </span>
   <span class="font10">however, </span>
   <span class="font10">injection </span>
   <span class="font10">maintenance </span>
   <span class="font10">mg/day </span>
   <span class="font10">organisation </span>
   <span class="font10">periods </span>
   <span class="font10">placebo-controlled </span>
   <span class="font10">possible, </span>
   <span class="font10">present </span>
   <span class="font10">px; </span>
   <span class="font10">rare </span>
   <span class="font10">shall </span>
   <span class="font10">small </span>
   <span class="font10">specific </span>
   <span class="font10">temporal </span>
   <span class="font10">treatment, </span>
   <span class="font10">type </span>
   <span class="font10">weight </span>
   <span class="font10">withdrawal </span>
   <span class="font10">work </span>
   <span class="font10">{font-family </span>
   <span class="font10">Approximately, </span>
   <span class="font10">Denmark </span>
   <span class="font10">Diener </span>
   <span class="font10">EFNS </span>
   <span class="font10">Goadsby </span>
   <span class="font10">MRI </span>
   <span class="font10">Rasmussen </span>
   <span class="font10">Tablets </span>
   <span class="font10">Tension-type </span>
   <span class="font10">Trigeminal </span>
   <span class="font10">autonomic </span>
   <span class="font10">avoid </span>
   <span class="font10">cause </span>
   <span class="font10">common </span>
   <span class="font10">controlled </span>
   <span class="font10">differential </span>
   <span class="font10">disease </span>
   <span class="font10">drugs </span>
   <span class="font10">font-size </span>
   <span class="font10">frequency </span>
   <span class="font10">infarction </span>
   <span class="font10">initiated </span>
   <span class="font10">insufficient </span>
   <span class="font10">maximum </span>
   <span class="font10">metoclopramide </span>
   <span class="font10">normally </span>
   <span class="font10">opioids </span>
   <span class="font10">oxygen </span>
   <span class="font10">pattern </span>
   <span class="font10">phonophobia </span>
   <span class="font10">photophobia </span>
   <span class="font10">possible </span>
   <span class="font10">reduction </span>
   <span class="font10">relief </span>
   <span class="font10">review </span>
   <span class="font10">significant </span>
   <span class="font10">specialist </span>
   <span class="font10">standard </span>
   <span class="font10">symptom </span>
   <span class="font10">trials </span>
   <span class="font10">triptans, </span>
   <span class="font10">Classification </span>
   <span class="font10">Consequently, </span>
   <span class="font10">Controlled </span>
   <span class="font10">Medication </span>
   <span class="font10">Oral </span>
   <span class="font10">Society </span>
   <span class="font10">Triptans </span>
   <span class="font10">amitriptyline </span>
   <span class="font10">cardiovascular </span>
   <span class="font10">causes </span>
   <span class="font10">clinical </span>
   <span class="font10">combined </span>
   <span class="font10">condition. </span>
   <span class="font10">conditions. </span>
   <span class="font10">considered </span>
   <span class="font10">decompression </span>
   <span class="font10">defined </span>
   <span class="font10">divided </span>
   <span class="font10">does </span>
   <span class="font10">double-blind </span>
   <span class="font10">double; </span>
   <span class="font10">effect, </span>
   <span class="font10">episodes </span>
   <span class="font10">factors, </span>
   <span class="font10">headache/facial </span>
   <span class="font10">health </span>
   <span class="font10">increasing </span>
   <span class="font10">indicate </span>
   <span class="font10">intracranial </span>
   <span class="font10">level </span>
   <span class="font10">nasal </span>
   <span class="font10">normal </span>
   <span class="font10">oestrogen-containing </span>
   <span class="font10">paracetamol </span>
   <span class="font10">pharmaceuticals </span>
   <span class="font10">phase </span>
   <span class="font10">prevalence </span>
   <span class="font10">randomized </span>
   <span class="font10">rarely </span>
   <span class="font10">reduced </span>
   <span class="font10">relation </span>
   <span class="font10">relatively </span>
   <span class="font10">reported </span>
   <span class="font10">spray </span>
   <span class="font10">substantial </span>
   <span class="font10">suspicion </span>
   <span class="font10">trial </span>
   <span class="font10">triptan </span>
   <span class="font10">&amp;lt; </span>
   <span class="font10">(e.g. </span>
   <span class="font10">-day </span>
   <span class="font10">./jama... </span>
   <span class="font10">./s--- </span>
   <span class="font10">Beta-blockers </span>
   <span class="font10">Biofeedback </span>
   <span class="font10">Clin </span>
   <span class="font10">Curr </span>
   <span class="font10">European </span>
   <span class="font10">Fig. </span>
   <span class="font10">General </span>
   <span class="font10">Ipsilateral </span>
   <span class="font10">JAMA </span>
   <span class="font10">Katsarava </span>
   <span class="font10">Salary </span>
   <span class="font10">Tfelt-Hansen </span>
   <span class="font10">accompanying </span>
   <span class="font10">acid </span>
   <span class="font10">affected </span>
   <span class="font10">aggravate </span>
   <span class="font10">aggravation </span>
   <span class="font10">and, </span>
   <span class="font10">avoided </span>
   <span class="font10">avoided. </span>
   <span class="font10">background </span>
   <span class="font10">bilateral </span>
   <span class="font10">blood </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">calendar </span>
   <span class="font10">central </span>
   <span class="font10">characteristics: </span>
   <span class="font10">consists </span>
   <span class="font10">described </span>
   <span class="font10">develop </span>
   <span class="font10">diagnosed </span>
   <span class="font10">different </span>
   <span class="font10">distinguish </span>
   <span class="font10">doses, </span>
   <span class="font10">ergotamine </span>
   <span class="font10">female </span>
   <span class="font10">form </span>
   <span class="font10">high </span>
   <span class="font10">ineffective </span>
   <span class="font10">instruction </span>
   <span class="font10">located </span>
   <span class="font10">maximally </span>
   <span class="font10">may, </span>
   <span class="font10">mechanisms </span>
   <span class="font10">mg, </span>
   <span class="font10">mg. </span>
   <span class="font10">microvascular </span>
   <span class="font10">migraine, </span>
   <span class="font10">moderate </span>
   <span class="font10">month </span>
   <span class="font10">months. </span>
   <span class="font10">musculoskeletal </span>
   <span class="font10">newly </span>
   <span class="font10">oestrogen </span>
   <span class="font10">offered </span>
   <span class="font10">overwhelming </span>
   <span class="font10">pain-free </span>
   <span class="font10">pain. </span>
   <span class="font10">patients, </span>
   <span class="font10">points </span>
   <span class="font10">positive </span>
   <span class="font10">possibly </span>
   <span class="font10">presenting </span>
   <span class="font10">presents </span>
   <span class="font10">previous </span>
   <span class="font10">probably </span>
   <span class="font10">rapid </span>
   <span class="font10">recommendations </span>
   <span class="font10">refer </span>
   <span class="font10">reference </span>
   <span class="font10">report </span>
   <span class="font10">section </span>
   <span class="font10">signs </span>
   <span class="font10">single </span>
   <span class="font10">sleep </span>
   <span class="font10">solid; </span>
   <span class="font10">special </span>
   <span class="font10">stabbing </span>
   <span class="font10">step </span>
   <span class="font10">suffer </span>
   <span class="font10">symptomatic </span>
   <span class="font10">systematic </span>
   <span class="font10">tablet </span>
   <span class="font10">taking </span>
   <span class="font10">therapy </span>
   <span class="font10">thorough </span>
   <span class="font10">twice </span>
   <span class="font10">used. </span>
   <span class="font10">versus </span>
   <span class="font10">visual </span>
   <span class="font10">years. </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">-month </span>
   <span class="font10">./.wnl... </span>
   <span class="font10">./S-()- </span>
   <span class="font10">According </span>
   <span class="font10">Ashina </span>
   <span class="font10">BMJ </span>
   <span class="font10">Bendtsen </span>
   <span class="font10">Caution </span>
   <span class="font10">Chronic </span>
   <span class="font10">Daily </span>
   <span class="font10">Epidemiol </span>
   <span class="font10">Episodic </span>
   <span class="font10">Exclude </span>
   <span class="font10">Furthermore, </span>
   <span class="font10">Kurth </span>
   <span class="font10">Lars </span>
   <span class="font10">Lesion </span>
   <span class="font10">Lyngberg </span>
   <span class="font10">MacGregor </span>
   <span class="font10">NSAID </span>
   <span class="font10">NSAIDs </span>
   <span class="font10">None. </span>
   <span class="font10">Stovner </span>
   <span class="font10">Summary </span>
   <span class="font10">Thorough </span>
   <span class="font10">Typical </span>
   <span class="font10">University </span>
   <span class="font10">Verapamil </span>
   <span class="font10">Welch </span>
   <span class="font10">Yes </span>
   <span class="font10">acetylsalicylic </span>
   <span class="font10">achieve </span>
   <span class="font10">active </span>
   <span class="font10">adjustment </span>
   <span class="font10">adolescents </span>
   <span class="font10">aged </span>
   <span class="font10">antiemetics </span>
   <span class="font10">average </span>
   <span class="font10">benign </span>
   <span class="font10">block </span>
   <span class="font10">bold </span>
   <span class="font10">bothersome </span>
   <span class="font10">brain </span>
   <span class="font10">branch </span>
   <span class="font10">carbamazepine/oxcarbazepine </span>
   <span class="font10">care </span>
   <span class="font10">causing </span>
   <span class="font10">checked </span>
   <span class="font10">children. </span>
   <span class="font10">choice </span>
   <span class="font10">cognitive </span>
   <span class="font10">comparable </span>
   <span class="font10">comprise </span>
   <span class="font10">concurrent </span>
   <span class="font10">conditions, </span>
   <span class="font10">connection </span>
   <span class="font10">courier; </span>
   <span class="font10">course </span>
   <span class="font10">day. </span>
   <span class="font10">depression </span>
   <span class="font10">depression, </span>
   <span class="font10">developed </span>
   <span class="font10">developing </span>
   <span class="font10">difficult </span>
   <span class="font10">drug </span>
   <span class="font10">em; </span>
   <span class="font10">exceed </span>
   <span class="font10">fatigue, </span>
   <span class="font10">features </span>
   <span class="font10">good </span>
   <span class="font10">gradually </span>
   <span class="font10">head </span>
   <span class="font10">health-care </span>
   <span class="font10">hormone </span>
   <span class="font10">i.e. </span>
   <span class="font10">ibuprofen </span>
   <span class="font10">identified </span>
   <span class="font10">improvement </span>
   <span class="font10">information, </span>
   <span class="font10">informed </span>
   <span class="font10">is, </span>
   <span class="font10">lack </span>
   <span class="font10">lesion </span>
   <span class="font10">life </span>
   <span class="font10">life-threatening </span>
   <span class="font10">lithium </span>
   <span class="font10">mirtazapine </span>
   <span class="font10">monotherapy. </span>
   <span class="font10">motor </span>
   <span class="font10">naproxen </span>
   <span class="font10">needed, </span>
   <span class="font10">neurology </span>
   <span class="font10">neurovascular </span>
   <span class="font10">new </span>
   <span class="font10">optimal </span>
   <span class="font10">oral </span>
   <span class="font10">overall </span>
   <span class="font10">patients. </span>
   <span class="font10">pericranial </span>
   <span class="font10">physician </span>
   <span class="font10">population-based </span>
   <span class="font10">posture </span>
   <span class="font10">pregnancy </span>
   <span class="font10">previously </span>
   <span class="font10">propranolol </span>
   <span class="font10">prospective </span>
   <span class="font10">pt;} </span>
   <span class="font10">raise </span>
   <span class="font10">recede </span>
   <span class="font10">receive </span>
   <span class="font10">reduce </span>
   <span class="font10">relapse </span>
   <span class="font10">remains </span>
   <span class="font10">remission </span>
   <span class="font10">reversible </span>
   <span class="font10">routine </span>
   <span class="font10">scans </span>
   <span class="font10">should, </span>
   <span class="font10">shown </span>
   <span class="font10">sinus </span>
   <span class="font10">stimuli </span>
   <span class="font10">studies. </span>
   <span class="font10">tablets. </span>
   <span class="font10">time </span>
   <span class="font10">tolerated </span>
   <span class="font10">triggered </span>
   <span class="font10">triptans. </span>
   <span class="font10">uncontrolled </span>
   <span class="font10">unphysiological </span>
   <span class="font10">valproate </span>
   <span class="font10">vascular </span>
   <span class="font10">weeks. </span>
   <span class="font10">young </span>
  </p>
 </body>
</html>
